Scientific tool company Zymo Research reported on Thursday the receipt of the CE IVD Mark for its EZ DNA Methylation-Lightning Kit for distribution within the European Union (EU) common market for clinical diagnostic and screening tests of diseases.
The company said the EZ DNA Methylation-Lightning Kit features a ready-to-use conversion reagent, which streamlines the workflow for completion in a little over an hour. The kit is available in spin-column and high-throughput 96-well formats.
According to the company, the chemical treatment of DNA with bisulfite is the prerequisite for many methylation-based diagnostic assays. Clinical diagnostic and screening tests in cancer and developmental diseases are utilizing methylation profiling of DNA to detect the presence of disease and guide treatment.
In addition, the desulphonation and cleanup of converted DNA are performed using unique spin technology, allowing ultra-low elution (10 µl) volumes. The kit achieves the highest conversion efficiencies for the most accurate downstream methylation analysis, said the company.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886